Back to bone: Optimising patient outcomes in metastatic bone disease

EAUN Industry Session by AMGEN

Saturday, 12 March
17:15 - 18:15

Location: Room 5
Chair: L. Drudge-Coates, London (GB)

Aims and objectives of this presentation
• To consider and discuss the impact of bone metastases in urological cancer, with a focus on the changing treatment approaches in Metastatic Castration Resistant Prostate Cancer (mCRPC) and the subsequent practical considerations in decision making, in a clinical consultation
• To provide an overview of symptoms and their causes in patients with bone metastases
• To provide an overview of symptom assessment tools and maximising their use in the clinical setting to optimise quality of life

17:15 - 17:20
Introduction
L. Drudge-Coates, London (GB)

17:20 - 17:45
The shifting prostate cancer treatment paradigm: Implications of increased patient survival
B. Tombal, Brussels (BE)

17:45 - 18:10
Optimising the patient clinical consultation: Symptom assessment tools
B. Quinn, London (GB)

18:10 - 18:15
Questions